Bronchitis Market Research Report - Forecast to 2027

Bronchitis Market Information: By Type (Acute Bronchitis, Chronic Bronchitis), by Diagnosis (Chest X-Ray, Sputum Tests, Pulmonary Function Test), by Devices (Drugs, Oxygen Therapy), by End-User (Hospitals, Clinics, Pharmacies)- Global Forecast Till 2027

ID: MRFR/Pharma/4303-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of the report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Synopsis of the Global Bronchitis Market

Bronchitis is nothing but the inflammation of the lining of bronchial tubes of the lungs. It is of two types, namely, acute and chronic bronchitis. Acute bronchitis, also known as a chest cold, is found to be very common and develops from a cold or other respiratory infection. On the other hand, chronic bronchitis is a severe condition which is characterized by constant irritation or inflammation of the lining of bronchial tubes. It is included in the Chronic Obstructive Pulmonary Disease (COPD). Shortness of breath, cough, slight fever and chills, production of mucus, fatigue, and chest discomfort are major symptoms of bronchitis. It can be diagnosed through various tests such as chest X-ray, sputum tests, and pulmonary function test.


The global bronchitis market is mainly driven by the increasing prevalence of lung diseases such as bronchitis, asthma, COPD, availability of drugs for the treatment, and drugs. Additionally, increasing number of diagnostic services for various chronic diseases and the use of technologically advanced devices for diagnosis also drive the growth of the market. Other factors supporting the market growth are an addiction to smoking and changing lifestyle. However, fierce competition among the existing market players restrains the growth of the market.


The global bronchitis market is expected to grow at a CAGR of 5.3% during the forecast period.


Segments  


The global bronchitis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into acute bronchitis and chronic bronchitis.


On the basis of diagnosis, the market is segmented into chest X-ray, sputum tests, and pulmonary function tests.


On the basis of treatment, the market is segmented into drugs and oxygen therapy. Drugs is further segmented into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics.


On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, research institutes, and others.


FIGURE 1: Global Bronchitis Market, by Region, 2016 (%)


 Bronchitis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology Bronchitis Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Global Bronchitis Market                  


The American bronchitis market is segmented into two regions, namely, North America and South America. North America is the largest market with huge patient pool, growing awareness about bronchitis treatment among the people and presence of major players in the market. South America is expected to be the fastest growing market with the increasing demand for diagnostic services.


In Europe, the bronchitis market is driven by the increasing focus on research and development activities for the treatment of chronic bronchitis. Germany and the U.K. occupy a first and second position in the European market which is driven by the increasing demand for diagnostic services for respiratory diseases and the emergence of new players in the market manufacturing various classes of drugs in the market.


The bronchitis market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing environmental population, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases among the adults. Additionally, growth in the number of people addicted to smoking and increasing number of patients with COPD fuel the market in this region.


The Middle Eastern and African market for bronchitis exhibits a steady rise with the growing awareness about causes, diagnosis, and treatment of chronic diseases. The demand for primary care services including diagnostic services for respiratory diseases fuels the market growth in Africa.


Key Players in the Global Bronchitis Market    


Some of the key players in this market are GlaxoSmithKline Pharmaceuticals Limited, Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, Pfizer Inc., Sanofi, Cathay Drug Company Inc., Kaiser Permanente Inc., AstraZeneca, and others.



Frequently Asked Questions (FAQ) :


Bronchitis is an inflammation of the bronchial tubes in the lungs. It can be acute or chronic.

Global Bronchitis Market is expected to exhibit a strong 5.3% CAGR over the forecast period till 2027.

The increasing prevalence of lung diseases is the major driver for the Bronchitis Market.

The Americas hold the dominant share in the Global Bronchitis Market.

Leading players in the Bronchitis Market include GSK, Boehringer Ingelheim, and Sanofi, among others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Bronchitis Market, by Type

6.1 Introduction

6.2 Acute Bronchitis

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Chronic Bronchitis

6.3.1 Market Estimates & Forecast, 2020–2027

7. Global Bronchitis Market, by Diagnosis

7.1 Introduction

7.2 Chest X-ray

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Sputum Test

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Pulmonary Function Test

7.4.1 Market Estimates & Forecast, 2020–2027

8. Global Bronchitis Market, by Treatment

8.1 Introduction

8.2 Drugs

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Oxygen Therapy

8.3.1 Market Estimates & Forecast, 2020–2027

9. Global Bronchitis Market, by End-User

9.1 Introduction

9.2 Hospital

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Clinics

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Pharmacies

9.4.1 Market Estimates & Forecast, 2020–2027

9.45 Research Institutes

9.5.1 Market Estimates & Forecast, 2020–2027

10. Global Bronchitis Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 GlaxoSmithKline Pharmaceuticals Limited

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Boehringer Ingelheim

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Dr. Reddy’s Laboratories Ltd

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Pfizer Inc.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Sanofi

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 The Cathay Drug Company Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Kaiser Permanente Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Diagnostic Tests Industry

14 Appendix


LIST OF TABLES

Table 1 Bronchitis Industry Synopsis, 2020–2027

Table 2 Global Bronchitis Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Bronchitis Market, by Region, 2020–2027, (USD Million)

Table 4 Global Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 5 Global Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 8 North America Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 9 North America Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 11 North America Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 12 US Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 13 US Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 US Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 15 US Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 21 South America Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Bronchitis Market, by End-User, 2020–2027, (USD Million)

Table 40 Middle East & Africa Bronchitis Market, by Type, 2020–2027, (USD Million)

Table 41 Middle East & Africa Bronchitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 Middle East & Africa Bronchitis Market, by Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Bronchitis Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bronchitis Market

Figure 3 Segmentation Market Dynamics for Bronchitis Market

Figure 4 Global Bronchitis Market Share, by Diagnosis, 2020

Figure 5 Global Bronchitis Market Share, by Treatment, 2020

Figure 6 Global Bronchitis Market Share, by End-User, 2020

Figure 7 Global Bronchitis Market Share, by Region, 2020

Figure 8 North America Bronchitis Market Share, by Country, 2020

Figure 9 Europe Bronchitis Market Share, by Country, 2020

Figure 10 Asia Pacific Bronchitis Market Share, by Country, 2020

Figure 11 Middle East & Africa Bronchitis Market Share, by Country, 2020

Figure 12 Global Bronchitis Market: Company Share Analysis, 2020 (%)

Figure 13 Glaxosmithkline Pharmaceuticals Limited: Key Financials

Figure 14 Glaxosmithkline Pharmaceuticals Limited: Segmental Revenue

Figure 16 Glaxosmithkline Pharmaceuticals Limited: Geographical Revenue

Figure 17 Boehringer Ingelheim: Key Financials

Figure 18 Boehringer Ingelheim: Segmental Revenue

Figure 19 Boehringer Ingelheim: Geographical Revenue

Figure 20 Dr. Reddy’s Laboratories Ltd: Key Financials

Figure 21 Dr. Reddy’s Laboratories Ltd: Segmental Revenue

Figure 22 Dr. Reddy’s Laboratories Ltd: Geographical Revenue

Figure 23 Pfizer Inc.: Key Financials

Figure 24 Pfizer Inc.: Segmental Revenue

Figure 25 Pfizer Inc.: Geographical Revenue

Figure 26 The Cathay Drug Company Inc.: Key Financials

Figure 27 The Cathay Drug Company Inc.: Segmental Revenue

Figure 28 The Cathay Drug Company Inc.: Geographical Revenue

Figure 29 Sanofi: Key Financials

Figure 30 Sanofi: Segmental Revenue

Figure 31 Sanofi: Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue